Background Severe trauma represents a major global public health burden and the
management of post-traumatic bleeding continues to challenge healthcare systems around …

The currently approved direct oral anticoagulants (DOACs) are increasingly used in clinical
practice. Although serious bleeding risks are lower with DOACs compared to vitamin K …

Background Diagnosing heparin-induced thrombocytopenia (HIT) at the bedside remains
challenging, exposing a significant number of patients at risk of delayed diagnosis or …

For more than a decade, US laboratories have failed to implement solutions to help their
clinicians in managing complex situations or patients on direct oral anticoagulants (DOACs) …

Background: The thrombin generation assay (TG) is a promising approach to measure the
degree of anticoagulation in patients treated with direct oral anticoagulants (DOAC). A …

Background Applying a single anti-Xa assay, calibrated to unfractionated heparin to
measure rivaroxaban, apixaban, and edoxaban would simplify laboratory procedures and …

Background Central venous catheters are prone to clotting, particularly in patients with
cancer. Although low-molecular-weight heparin and direct oral anticoagulants, such as …

Background Restoring hemostasis in patients on oral anticoagulants presenting with major
hemorrhage (MH) or before surgical intervention has changed, with the replacement of …

(1) Background: Direct oral anticoagulants (DOACs) require monitoring in some critical
clinical situations. The specific tests for DOAC monitoring are not yet available in all labs …

Direct oral anticoagulants (DOACs) describe a group of drugs that have emerged over the
last decade, which are active against either activated factor II (or thrombin; IIa) or activated …